After many long and arduous years of research and development, MoAbs are finally beginning to play a pivotal role not only in cancer therapeutics, but in other disease states as well. Laboratory techniques enabling the chimerization or humanization of antibodies has resulted in significant improvement in the tolerability of these compounds. Additionally, advancements in bioreactor capabilities have enabled companies to meet commercial demands for these products. Developments in recombinant technology involving linkers, toxins, and radiolabeled isotopes will lead to the availability of more MoAbs for routine clinical use. Future studies will center on genomics, and genetic mutations found within cells that affect cellular signaling pathways. Detailed knowledge of these pathways will allow for combination regimens that concurrently target multiple areas in the malignant transformation of a cell. This opens the door for highly explicit treatment regimens that minimize toxicity to healthy cells, while maximizing toxicity to malignant clones.

0 0

Post a comment